Clinical Value of Serum and Exhaled Breath Condensate miR-186 and IL-1β Levels in Non-Small Cell Lung Cancer

Abstract

Objective: Our study aimed to investigate the expression level and clinical significance of serum and exhaled breath condensate miR-186 and IL-1β in non-small cell lung cancer patients. Methods: The serum and exhaled breath condensate specimens of 62 non-small cell lung cancer patients and 60 healthy controls were collected to detect miR-186 expression levels by real-time fluorescent quantitative PCR. Enzyme linked immunosorbent assay was applied to examine IL-1β concentration. Statistical analyses were used to evaluate the correlation between miR-186 and IL-1β in serum and clinicopathological features, traditional serum tumor markers, and inflammatory markers. The diagnostic efficacy of miR-186 and IL-1β for non-small cell lung cancer was evaluated by receiver operating characteristic curve analysis. The correlation between miR-186 and IL-1β was determined. Results: ① The relative expression level of miR-186 was greatly reduced in the serum and EBC of patients with non-small cell lung cancer, and the miR-186 expression level was reduced in different TNM stages of non-small cell lung cancer, from the early to later stages. ② The IL-1β concentration in serum and exhaled breath condensate of patients with non-small cell lung cancer was increased. ③ Serum miR-186 and IL-1β levels were closely related to lymph node metastasis, and the low expression of serum miR-186 and the high concentration of IL-1β were associated with higher serum carcinoembryonic antigen, C-reactive protein, and erythrocyte sedimentation rate levels. ④ ROC curve analysis showed that exhaled breath condensate miR-186 had higher area under the curve than serum miR-186, and the combined detection showed higher diagnostic efficacy than the separate detection. In addition, the combined detection of IL-1β and miR-186 has a larger AUC than the separate detection of both. ⑤ The correlation between serum miR-186 and IL-1β was negative. Conclusion: miR-186 and IL-1β are expected to be potential diagnostic biomarkers for non-small cell lung cancer.

Prognosis value of IL-6, IL-8, and IL-1β in serum of patients with lung cancer: A fresh look at interleukins as a biomarker

“…Compared with those patients with early-stage disease, serum levels of CEA and IL-8 in patients with late-stage lung cancer were significantly increased, but the levels of IL-1β and IL-6 had no change significantly, which is inconsistent with the results of Xie et al. [ 37 ] and may be related to the number of cases and the inclusion and exclusion criteria used.…”

A Systematic Review of Progress toward Unlocking the Power of Epigenetics in NSCLC: Latest Updates and Perspectives

“…Xie et al noted that miR-186 was downregulated in both serum and EBC of NSCLC patients, and this was linked to lymph node metastasis. Furthermore, they observed a connection between low expression of serum miR-186 and higher serum carcinoembryonic antigen, C-reactive protein, and erythrocyte sedimentation rate [ 44 ]. Based on miRNAs from EBC, Perez-Sanchez et al proposed two diagnostic signatures: the first for discrimination between lung cancer patients and healthy control groups ( miR-4507 , miR-6777-5p , and miR-451 ) and the second for recognition of LUAD from LUSC ( miR-4529-3p , miR-8075 , and miR-7704 ) [ 45 ].…”

IL-1β-Triggered Long Non-coding RNA CHRF Induces Non-Small Cell Lung Cancer by Modulating the microRNA-489/Myd88 Axis

“…Of note, lncRNA CHRF has been tested to be highly expressed in cervical cancer, gastric cancer and prostate cancer in contribution to malignant cell proliferation, migration and drug resistance 20 - 22 . Recently, IL-1β as a classical pro-inflammatory factor possesses promoting effect on proliferation and metastasis of NSCLC cells 23 . Also, high expression of IL-1β and lncRNA CHRF has been detected in mice with sepsis while knockdown of lncRNA CHRF reduces inflammatory reaction 24 .…”